Posted by Michael Wonder on 02 Apr 2023
Samsung Bioepis receives positive CHMP opinion for eculizumab biosimilar, Epysqli
31 March 2023 - Epysqli, a biosimilar referencing Soliris (eculizumab), is Samsung Bioepis’ first biosimilar in haematology to be recommended for marketing authorisation by the EMA.
Samsung Bioepis today announced that the EMA's CHMP has adopted a positive opinion for Epysqli, a biosimilar referencing Soliris (eculizumab), also known as SB12.
